Deliverables

Contents

Lead organisation

D1.1

Report with guidance on health economic modelling of personalised medicine

iMTA

D1.2

Report providing a checklist to assess the methodological quality of model-based economic evaluations of personalised medicine

iMTA

D2.1

Report on the thematic outcomes of a workshop dealing with enhanced health/pharmaco-economic models for personalised medicine

SYREON

D4.1

Report on the major findings from the expert and stakeholder interviews with regard to benefits and challenges of personalised medicine for the European Social Models of Health Care

AIT

D6.1

Plan for the Data Management throughout the project

AIT


Project results scheduled for 2021

Deliverables

Contents

Lead organisation

D2.2

Cost-effectiveness models for three case studies

SYREON

D2.3

Budget impact models for three case studies

SYREON

D2.4

Report with recommendation on the refinement of the guidance developed D1.1

SYREON

D2.5

Developed Models populated with input data from three EU Member States

SYREON

D3.1

Report on a set of appropriate financing and payment models for personalised medicine for different types of health care systems in EU

UOXF

D3.2

Report with action plan for the adoption of appropriate financing and payment models for personalised medicine across the EU

UOXF

D4.2

Report on “The Benefits & Challenges of Personalised Medicine for the European Social Models of Health Care” with scenarios for personalised medicine futures, enhancing personalised medicine networks for health benefits, institutional support for personalised medicine and the significance of personalised medicine for the citizen

AIT

D5.1

Technical report on the outcome of the workshop dealing with enhanced health/pharmaco-economic models for personalised medicine

DLR

D5.2

Technical report on the workshop on financing and payment models in the context of personalised medicine

DLR

D5.3

Technical report on the outcomes of the Stakeholder Conference on “How can health/pharmaco-economic models along with financing and payment models support the sustainable implementation of personalised medicine in our health systems?”

DLR

Publications

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine
Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Maureen Rutten-van Mölken on behalf of the HEcoPerMed Consortium
in: PharmacoEconomics (2021)

The paper is open access online, find it here:
https://link.springer.com/article/10.1007/s40273-021-01010-